Details of Drug

Drug General Information (ID: D1151)
Drug Name	Nizatidine
Drug Type	Small molecule
Drug Synonymous	Acinon; Antizid; Axid; Calmaxid; Cronizat; Distaxid; Galitidin; Gastrax; Naxidine; Niatidine; Nizatidina; Nizatidinum; Nizax; Nizaxid; Panaxid; Tazac; Ulcosol; Ulxid; Zanizal; Zinga; Axid Ar; Nizatidina [Spanish]; Nizatidinum [Latin]; Splendil ER; LY 139037; Acinon (TN); Axid (TN); LY-139037; Tazac (TN); ZE-101; ZL-101; Nizatidine (JAN/USP/INN); Nizatidine [USAN:BAN:INN:JAN]; N-(2-(((2-((Dimethylamino)methyl)-4-thiazolyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamin; (E)-1-N'-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({2-[(dimethylamino)methyl]-1,3-thiazol-4-yl}methyl)thio]ethyl}-N'-methyl-2-nitroethene-1,1-diamine Click to Show/Hide
Disease Class	DA22: Gastro-oesophageal reflux disease
Therapeutic Class	Antiulcer Agents
Structure
Structure	3D Structure		2D Structure
Formula	C12H21N5O2S2
InChI	1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6+
InChIKey	SGXXNSQHWDMGGP-IZZDOVSWSA-N
Canonical SMILES	CNC(=C[N+](=O)[O-])NCCSCC1=CSC(=N1)CN(C)C
External Link
	Pubchem ID	3033637
	CAS Number	76963-41-2
	CHEBI ID	7601
	TTD ID	D0Q9DK
	INTEDE ID	DR2187
	VARIDT ID	DR00263

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM001 Affected gastrointestinal absorption AM004 Affected intra/extra-hepatic metabolism AM006 Pharmacodynamic additive effects BM004 Adsorption BM005 Altered gastric pH BM017 CYP450 enzyme inhibition BM049 Increased risk of atrioventricular block BM051 Increased risk of bradycardia BM081 Increased risk of ventricular arrhythmias
Relation Graph

Full list of drugs interacting with Nizatidine
Affected gastrointestinal absorption
	Adsorption					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0021		Activated charcoal	C	5462310	Moderate		Inter Info	[28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51], [52]
	Altered gastric pH					Drug Num: 50
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0116		Atazanavir	C38H52N6O7	148192	Major		Inter Info	[1], [2], [3], [4], [5], [6], [7], [8]
D0428		Dasatinib	C22H26ClN7O2S	3062316	Major		Inter Info	[9]
D1124		Neratinib	C30H29ClN6O3	9915743	Major		Inter Info	[10], [11]
D1232		Pazopanib	C21H23N7O2S	10113978	Major		Inter Info	[1], [12], [13], [14], [15], [16]
D1404		Rilpivirine	C22H18N6	6451164	Major		Inter Info	[17]
D1459		Selpercatinib	C29H31N7O3	134436906	Major		Inter Info	[1], [18]
D0013		Acetohexamide	C15H20N2O4S	1989	Moderate		Inter Info	[20], [21], [22], [23]
D0595		Erlotinib	C22H23N3O4	176870	Moderate		Inter Info	[10], [1], [24], [25]
D0713		Gefitinib	C22H24ClFN4O3	123631	Moderate		Inter Info	[26]
D0727		Glimepiride	C24H34N4O5S	3476	Moderate		Inter Info	[20], [21], [22], [23]
D0008		Acalabrutinib	C26H23N7O2	71226662	Moderate		Inter Info	[27]
D0141		Bacampicillin	C21H27N3O7S	441397	Moderate		Inter Info	[82], [83]
D0195		Bosutinib	C26H29Cl2N5O3	5328940	Moderate		Inter Info	[1], [84]
D0278		Cefditoren	C19H18N6O5S3	9870843	Moderate		Inter Info	[86]
D0288		Cefpodoxime	C15H17N5O6S2	6335986	Moderate		Inter Info	[82], [87], [88], [83]
D0297		Cefuroxime	C16H16N4O8S	5479529	Moderate		Inter Info	[82], [87], [88], [83]
D0302		Ceritinib	C28H36ClN5O3S	57379345	Moderate		Inter Info	[89]
D0325		Chlorpropamide	C10H13ClN2O3S	2727	Moderate		Inter Info	[20], [21], [22], [23]
D0406		Dabrafenib	C23H20F3N5O2S2	44462760	Moderate		Inter Info	[10], [1], [90], [91], [92], [93], [94]
D0409		Dacomitinib	C24H25ClFN5O2	11511120	Moderate		Inter Info	[1], [95]
D0439		Delavirdine	C22H28N6O3S	5625	Moderate		Inter Info	[96]
D0692		Fosamprenavir	C25H36N3O9PS	131536	Moderate		Inter Info	[99]
D0728		Glipizide	C21H27N5O4S	3478	Moderate		Inter Info	[20], [21], [22], [23]
D0730		Glyburide	C23H28ClN3O5S	3488	Moderate		Inter Info	[20], [21], [22], [23]
D0867		Itraconazole	C35H38Cl2N8O4	55283	Moderate		Inter Info	[100], [101], [102], [103]
D0880		Ketoconazole	C26H28Cl2N4O4	456201	Moderate		Inter Info	[105], [100], [106], [107], [108], [1], [109], [110], [111], [112]
D0894		Lapatinib	C29H26ClFN4O4S	208908	Moderate		Inter Info	[1], [113]
D0898		Ledipasvir	C49H54F2N8O6	67505836	Moderate		Inter Info	[115]
D1136		Nilotinib	C28H22F3N7O	644241	Moderate		Inter Info	[10], [1], [116]
D1258		Pexidartinib	C20H15ClF3N5	25151352	Moderate		Inter Info	[118]
D1315		Posaconazole	C37H42F2N8O4	468595	Moderate		Inter Info	[119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129]
D1601		Tolazamide	C14H21N3O3S	5503	Moderate		Inter Info	[20], [21], [22], [23]
D1603		Tolbutamide	C12H18N2O3S	5505	Moderate		Inter Info	[20], [21], [22], [23]
D1686		Velpatasvir	C49H54N8O8	67683363	Moderate		Inter Info	[131]
D0395		Cyanocobalamin	C63H88CoN14O14P	5311498	Minor		Inter Info	[132], [133], [134], [135], [136]
D0539		Duloxetine	C18H19NOS	60835	Minor		Inter Info	[137]
D0573		Enoxacin	C15H17FN4O3	3229	Minor		Inter Info	[138], [139]
D0049		Aluminum hydroxide	AlH3O3	10176082	Minor		Inter Info	[140], [141], [54], [142], [143], [144], [145], [146], [147], [148], [149], [150]
D0133		Axitinib	C22H18N4OS	6450551	Minor		Inter Info	[151]
D0236		Calcium carbonate	CCaO3	10112	Minor		Inter Info	[140], [141], [54], [142], [143], [144], [145], [146], [147], [148], [149], [150]
D0967		Magaldrate	AlHMgO5S+2	3086011	Minor		Inter Info	[140], [141], [54], [142], [143], [144], [145], [146], [147], [148], [149], [150]
D0968		Magnesium carbonate	CMgO3	11029	Minor		Inter Info	[140], [141], [54], [142], [143], [144], [145], [146], [147], [148], [149], [150]
D0973		Magnesium hydroxide	H2MgO2	14791	Minor		Inter Info	[140], [141], [54], [142], [143], [144], [145], [146], [147], [148], [149], [150]
D0974		Magnesium oxide	MgO	14792	Minor		Inter Info	[140], [141], [54], [142], [143], [144], [145], [146], [147], [148], [149], [150]
D0989		Mecobalamin	C63H91CoN13O14P	10898559	Minor		Inter Info	[133], [134], [136]
D1313		Ponatinib	C29H27F3N6O	24826799	Minor		Inter Info	[10], [152]
D1328		Prasugrel	C20H20FNO3S	6918456	Minor		Inter Info	[153], [154]
D1377		Raltegravir	C20H21FN6O5	54671008	Minor		Inter Info	[155]
D1480		Sodium bicarbonate	CHNaO3	516892	Minor		Inter Info	[140], [141], [54], [142], [143], [144], [145], [146], [147], [148], [149], [150]
D1701		Vismodegib	C19H14Cl2N2O3S	24776445	Minor		Inter Info	[10], [1], [156]
Affected intra/extra-hepatic metabolism
	CYP450 enzyme inhibition					Drug Num: 3
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0064		Aminophylline	C16H24N10O4	9433	Moderate		Inter Info	[53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63], [64], [65], [66], [67], [68], [69], [70], [71], [72], [73], [74], [75], [76], [77], [78], [79], [80], [81]
D1201		Oxtriphylline	C12H21N5O3	656652	Moderate		Inter Info	[53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63], [64], [65], [66], [67], [68], [69], [70], [71], [72], [73], [74], [75], [76], [77], [78], [79], [80], [81]
D1570		Theophylline	C7H8N4O2	2153	Moderate		Inter Info	[53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63], [64], [65], [66], [67], [68], [69], [70], [71], [72], [73], [74], [75], [76], [77], [78], [79], [80], [81]
Pharmacodynamic additive effects
	Increased risk of bradycardia					Drug Num: 6
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1474		Siponimod	C29H35F3N2O3	44599207	Major		Inter Info	[10], [19]
D0204		Brigatinib	C29H39ClN7O2P	68165256	Moderate		Inter Info	[85]
D0661		Fingolimod	C19H33NO2	107970	Moderate		Inter Info	[97], [98]
D0868		Ivabradine	C27H36N2O5	132999	Moderate		Inter Info	[10], [104]
D0897		Lasmiditan	C19H18F3N3O2	11610526	Moderate		Inter Info	[114]
D1211		Ozanimod	C23H24N4O3	52938427	Moderate		Inter Info	[117]
	Increased risk of ventricular arrhythmias					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1569		Thalidomide	C13H10N2O4	5426	Moderate		Inter Info	[10], [1], [130]

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Drug interactions. Atazanavir and acid-reducing agents. TreatmentUpdate 18 (2006): 4. [PMID: 17209238]
3	Klein CE, Chiu YL, Cai Y, et al. "Effects of Acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir." J Clin Pharmacol 48 (2008): 553-62. [PMID: 18440920]
4	Product Information. Evotaz (atazanavir-cobicistat). Bristol-Myers Squibb, Princeton, NJ.
5	Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
6	Ray JE, Marriott D, Bloch MT, McLachlan AJ "Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic." Br J Clin Pharmacol 60 (2005): 291-9. [PMID: 16120068]
7	Agarwala S, Persson A, Eley T, et al "Effect of famotidine 20 and 40 mg dosing regimens on the bioavailability of atazanavir with ritonavir in combination with tenofovir in healthy subjects".
8	Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P "Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study." Aids 14 (2000): 1333-9. [PMID: 10930147]
9	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
10	Cerner Multum, Inc. "Australian Product Information.".
11	Product Information. Nerlynx (neratinib). Puma Biotechnology, Inc., Los Angeles, CA.
12	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
13	Product Information. Votrient (pazopanib). GlaxoSmithKline, Research Triangle Park, NC.
14	Tan AR, Gibbon DG, Stein MN, et al. "Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors." Cancer Chemother Pharmacol 71 (2013): 1635-43. [PMID: 23636448]
15	van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG "Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective." Lancet Oncol 15 (2014): e315-e326. [PMID: 24988935]
16	Yu G, Zheng QS, Wang DX, Zhou HH, Li GF "Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye." Lancet Oncol 15 (2014): e469-70. [PMID: 25281461]
17	Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
18	Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
19	Product Information. Mayzent (siponimod). Novartis Pharmaceuticals, East Hanover, NJ.
20	Dey NG, Castleden CM, Ward J, et al "The effect of cimetidine on tolbutamide kinetics." Br J Clin Pharmacol 16 (1983): 438-40. [PMID: 6626438]
21	Feely J, Collins WCJ, Cullen CM, et al. "Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H2-receptor antagonists." Br J Clin Pharmacol 35 (1993): 321-3. [PMID: 8471413]
22	Kubacka RT, Antal EJ, Juhl RP "The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics." Br J Clin Pharmacol 23 (1987): 743-51. [PMID: 3111514]
23	Lee K, Mize R, Lowenstein SR "Glyburide-induced hypoglycemia and ranitidine." Ann Intern Med 107 (1987): 261-2. [PMID: 3111324]
24	Duong S, Leung M "Should the concomitant use of erlotinib and acid-reducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents." J Oncol Pharm Pract 17 (2011): 448-52. [PMID: 20716581]
25	Product Information. Tarceva (erlotinib). Genentech, South San Francisco, CA.
26	Product Information. Iressa (gefitinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
27	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
28	Bonuccelli U, Piccini P, Del Dotto P, Pavese N, D'Antonio P, Muratorio A "Apomorphine test in de novo Parkinson's disease." Funct Neurol 7 (1992): 295-8. [PMID: 1427361]
29	Chernish SM, Wolen RL, Rodda BE "Adsorption of propoxyphene hydrochloride by activated charcoal." Clin Toxicol 5 (1972): 317-29. [PMID: 5073815]
30	Decker WJ, Shpall RA, Corby DG "Inhibition of aspirin absorption by activated charcoal and apomorphine." Clin Pharmacol Ther 10 (1969): 710-3. [PMID: 5808464]
31	Dolgin JG, Nix DE, Sanchez J, Watson WA "Pharmacokinetic simulation of the effect of multiple-dose activated charcoal in phenytoin poisoning: report of two pediatric cases." DICP 25 (1991): 646-9. [PMID: 1877275]
32	Farrar HC, Herold DA, Reed MD "Acute valproic acid intoxication: enhanced drug clearance with oral-activated charcoal." Crit Care Med 21 (1993): 299-301. [PMID: 8428486]
33	Gadgil SD, Damle SR, Advani SH, Vaidya AB "Effect of activated charcoal on the pharmacokinetics of high-dose methotrexate." Cancer Treat Rep 66 (1982): 1169-71. [PMID: 7083219]
34	Glab WN, Corby DG, Decker WJ, Coldiron VR "Decreased absorption of propoxyphene by activated charcoal." J Toxicol Clin Toxicol 19 (1982): 129-38. [PMID: 6125599]
35	Herrington AM, Clifton GD "Toxicology and management of acute drug ingestions in adults." Pharmacotherapy 15 (1995): 182-200. [PMID: 7624266]
36	Howard CE, Roberts RS, Ely DS, Moye RA "Use of multiple-dose activated charcoal in phenytoin toxicity." Ann Pharmacother 28 (1994): 201-3. [PMID: 8173135]
37	Ilkhanipour K, Yealy DM, Krenzelok EP "Activated charcoal surface area and its role in multiple-dose charcoal therapy." Am J Emerg Med 11 (1993): 583-5. [PMID: 8240556]
38	Karkkainen S, Neuvonen PJ "Effect of oral charcoal and urine pH on dextropropoxyphene pharmacokinetics." Int J Clin Pharmacol Ther Toxicol 23 (1985): 219-25. [PMID: 2987139]
39	Kivisto KT, Neuvonen PJ "The effect of cholestyramine and activated charcoal on glipizide absorption." Br J Clin Pharmacol 30 (1990): 733-6. [PMID: 2271372]
40	Knadler MP, Bergstrom RF, Callaghan JT, Obermeyer BD, Rubin A "Absorption studies of the H2-blocker nizatidine." Clin Pharmacol Ther 42 (1987): 514-20. [PMID: 2890459]
41	Naveau S, Bonhomme L, Preaux N, Chaput JC "A pure charcoal suspension for colonoscopic tattoo." Gastrointest Endosc 37 (1991): 624-5. [PMID: 1756921]
42	Neuvonen PJ "Clinical pharmacokinetics of oral activated charcoal in acute intoxications." Clin Pharmacokinet 7 (1982): 465-89. [PMID: 6761032]
43	Orisakwe OE "Activated charcoal: is failure to use it negligence or ignorance?" South Med J 87 (1994): 165-8. [PMID: 8115876]
44	Park GD, Spector R, Goldberg MJ, Johnson GF "Expanded role of charcoal therapy in the poisoned and overdosed patient." Arch Intern Med 146 (1986): 969-73. [PMID: 3516107]
45	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
46	Reed MD "Oral activated charcoal therapy." Am J Emerg Med 6 (1988): 318. [PMID: 3370115]
47	Rowden AM, Spoor JE, Bertino JS, Jr "The effect of activated charcoal on phenytoin pharmacokinetics." Ann Emerg Med 19 (1990): 1144-7. [PMID: 2221521]
48	Saetta JP "Gastric decontaminating procedures: is it time to call a stop?" J R Soc Med 86 (1993): 396-9. [PMID: 8371247]
49	Scheufler E, Bos I "Influence of peroral charcoal on pharmacokinetics and intestinal toxicity of intravenously given methotrexate." Arch Int Pharmacodyn Ther 261 (1983): 180-5. [PMID: 6838279]
50	Wakabayashi Y, Maruyama S, Hachimura K, Ohwada T "Activated charcoal interrupts enteroenteric circulation of phenobarbital." J Toxicol Clin Toxicol 32 (1994): 419-24. [PMID: 8057401]
51	Watson WA "Factors influencing the clinical efficacy of activated charcoal." Drug Intell Clin Pharm 21 (1987): 160-6. [PMID: 3549212]
52	Wing LM, Miners JO, Birkett DJ, et al "Lidocaine disposition: sex differences and effects of cimetidine." Clin Pharmacol Ther 35 (1984): 695-701. [PMID: 6713782]
53	Anderson JR, Poklis A, Slavin RG "A fatal case of theophylline intoxication." Arch Intern Med 143 (1983): 559-60. [PMID: 6830388]
54	Bachmann KA, Sullivan TJ, Jauregui L, Reese J, Miller K, Levine L "Drug interactions of h-2-receptor antagonists." Scand J Gastroenterol 29 (1994): 14-9. [PMID: 7863246]
55	Bauman JH, Kimelblatt BJ, Caraccio TR, Silverman HM, Simon GI, Beck GJ "Cimetidine-theophylline interaction: report of four patients." Ann Allergy 48 (1982): 100-2. [PMID: 6121526]
56	Boehning W "Effect of cimetidine and ranitidine on plasma theophylline in patients with chronic obstructive airways disease treated with theophylline and corticosteroids." Eur J Clin Pharmacol 38 (1990): 43-5. [PMID: 2328746]
57	Campbell MA, Plachetka JR, Jackson JE, Moon JF, Finley PR "Cimetidine decreases theophylline clearance." Ann Intern Med 95 (1981): 68-9. [PMID: 7247131]
58	Dal Negro R, Pomari C, Turco P "Famotidine and theophylline pharmacokinetics. An unexpected cimetidine-like interaction in patients with chronic obstructive pulmonary disease." Clin Pharmacokinet 24 (1993): 255-8. [PMID: 8462230]
59	Fenje PC, Isles AF, Baltodano A, MacLeod SM, Soldin S "Interaction of cimetidine and theophylline in two infants." Can Med Assoc J 126 (1982): 1178. [PMID: 7074441]
60	Fernandes E, Melewicz FM "Ranitidine and theophylline." Ann Intern Med 100 (1984): 459. [PMID: 6320702]
61	Hardman JG, Gilman AG, Limbird LE eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed." New York, NY: McGraw-Hill (1995):.
62	Hegman GW, Gilbert RP "Ranitidine-theophylline interaction--fact or fiction?" Ann Pharmacother 25 (1991): 21-5. [PMID: 2008782]
63	Hsu K, Garton A, Sproule BJ, Tam YK, Leggatt D, Herbert FA "The influence of orally administered cimetidine and theophylline on the elimination of each drug in patients with chronic airways obstruction." Am Rev Respir Dis 130 (1984): 740-3. [PMID: 6497156]
64	Jackson JE, Powell JR, Wandell M, Bentley J, Dorr R "Cimetidine decreases theophylline clearance." Am Rev Respir Dis 123 (1981): 615-7. [PMID: 7023306]
65	Kehoe WA, Sands CD, Long LF, et al "Effect of ranitidine on theophylline metabolism in healthy Koreans living in China." Ann Pharmacother 30 (1996): 133-7. [PMID: 8835044]
66	Kelly HW "Lack of evidence for reduction of theophylline clearance by ranitidine." Am J Med 86 (1989): 629-32. [PMID: 2712078]
67	Kelly HW, Powell JR, Donohue JF "Ranitidine at very large doses does not inhibit theophylline elimination." Clin Pharmacol Ther 39 (1986): 577-81. [PMID: 3698466]
68	Lin JH, Chremos AN, Chiou R, Yeh KC, Williams R "Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers." Br J Clin Pharmacol 24 (1987): 669-72. [PMID: 2893637]
69	Lofgren RP, Gilbertson RA "Cimetidine and theophylline." Ann Intern Med 96 (1982): 378. [PMID: 6800293]
70	Loi CM, Parker BM, Cusack BJ, Vestal RE "Aging and drug interactions .3. individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism in healthy male and female nonsmokers." J Pharmacol Exp Ther 280 (1997): 627-37. [PMID: 9023273]
71	Ohashi K, Sakamoto K, Sudo T, Tateishi T, Fujimura A, Shiga T, Ebihara A "Effects of diltiazem and cimetidine on theophylline oxidative metabolism." J Clin Pharmacol 33 (1993): 1233-7. [PMID: 8126258]
72	Powell JR, Rogers JF, Wargin WA, Cross RE, Eshelman FN "Inhibition of theophylline clearance by cimetidine but not ranitidine." Arch Intern Med 144 (1984): 484-6. [PMID: 6322709]
73	Pride M, Deamer RL "Over-the-counter cimetidine and theophylline interaction." Am Fam Physician 52 (1995): 2180. [PMID: 7484712]
74	Reitberg DP, Bernhard H, Schentag JJ "Alteration of theophylline clearance and half-life by cimetidine in normal volunteers." Ann Intern Med 95 (1981): 582-5. [PMID: 7294546]
75	Roy AK, Cuda MP, Levine RA "Induction of theophylline toxicity and inhibition of clearance rates by ranitidine." Am J Med 85 (1988): 525-7. [PMID: 3177399]
76	Schwartz JI, Bachmann KA, Bond LW, Mahajan VK "Impact of cimetidine on the pharmacokinetics of the theophylline." Clin Pharm 1 (1982): 534-8. [PMID: 7185539]
77	Skinner MH, Lenert L, Blaschke TF "Theophylline toxicity subsequent to ranitidine administration: a possible drug-drug interaction." Am J Med 86 (1989): 129-32. [PMID: 2910084]
78	Upton RA "Pharmacokinetic interactions between theophylline and other medication (Part II)." Clin Pharmacokinet 20 (1991): 135-50. [PMID: 1709398]
79	Verdiani P, Di Carlo S, Baronti A "Famotidine effects on theophylline pharmacokinetics in subjects affected by COPD: comparison with cimetidine and placebo." Chest 94 (1988): 807-10. [PMID: 3168576]
80	Weinberger MM, Smith G, Milavetz G, Hendeles L "Decreased clearance of theophylline due to cimetidine ." N Engl J Med 304 (1981): 672. [PMID: 7453751]
81	Bachmann K, Sullivan TJ, Reese JH, Jauregui L, Miller K, Scott M, Yeh KC, Stepanavage M, King JD, Schwartz J "Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease." J Clin Pharmacol 35 (1995): 529-35. [PMID: 7657856]
82	Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71. [PMID: 9784931]
83	Sommers DK, van Wyk M, Moncrieff J, Schoeman HS "Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil." Br J Clin Pharmacol 18 (1984): 535-9. [PMID: 6091711]
84	Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
85	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
86	Product Information. Spectracef (cefditoren). TAP Pharmaceuticals Inc, Deerfield, IL.
87	Hughes GS, Heald DL, Barker KB, et al. "The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil." Clin Pharmacol Ther 46 (1989): 674-85. [PMID: 2557183]
88	Saathoff N, Lode H, Neider K, et al "Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist." Antimicrob Agents Chemother 36 (1992): 796-800. [PMID: 1354432]
89	Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
90	Product Information. Aciphex (rabeprazole) Janssen Pharmaceuticals, Titusville, NJ.
91	Product Information. Dexilant (dexlansoprazole). Takeda Pharmaceuticals America, Lincolnshire, IL.
92	Product Information. Prevacid (lansoprazole). TAP Pharmaceuticals Inc, Deerfield, IL.
93	Product Information. Tafinlar (dabrafenib). GlaxoSmithKline, Research Triangle Park, NC.
94	Product Information. Zantac (ranitidine). Glaxo Wellcome, Research Triangle Park, NC.
95	Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
96	Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
97	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
98	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod).".
99	Product Information. Lexiva (fosamprenavir). GlaxoSmithKline, Research Triangle Park, NC.
100	Blum RA, D'Andrea DT, Florentino BM, et al "Increased gastric pH and the bioavailability of fluconazole and ketoconazole." Ann Intern Med 114 (1991): 755-7. [PMID: 2012358]
101	Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32. [PMID: 10730911]
102	Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33. [PMID: 2330488]
103	Product Information. Sporonox (itraconazole). Janssen Pharmaceutica, Titusville, NJ.
104	Product Information. Corlanor (ivabradine). Amgen USA, Thousand Oaks, CA.
105	Adachi M, Hinatsu Y, et.al "Improved dissolution and absorption of ketoconazole in the presence of organic acids as pH-modifiers." Eur J Pharm Sci 76 (2015): 225-30. [PMID: 25988287]
106	Carlson JA, Mann HJ, Canafax DM "Effect of pH on disintegration and dissolution of ketoconazole tablets." Am J Hosp Pharm 40 (1983): 1334-6. [PMID: 6310994]
107	Cerner Multum, Inc "ANVISA Bulario Eletrnico.".
108	Cerner Multum, Inc. "Canadian Product Information.".
109	Chin TWF, Loeb M, Fong IW "Effects of an acidic beverage (coca-cola) on absorption of ketoconazole." Antimicrob Agents Chemother 39 (1995): 1671-5. [PMID: 7486898]
110	Piscitelli SC, Goss TF, Wilton JH, D'Andrea DT, Goldstein H, Schentag JJ "Effects of ranitidine and sucralfate on ketoconazole bioavailability." Antimicrob Agents Chemother 35 (1991): 1765-71. [PMID: 1952845]
111	Product Information. Ketoconazole (ketoconazole). Mylan Pharmaceuticals Inc, Morgantown, WV.
112	Van der Meer JW, Keuning JJ "The influence of gastric acidity on the bio-availability of ketoconazole." J Antimicrob Chemother 6 (1980): 552-4. [PMID: 6253434]
113	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
114	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
115	Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
116	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
117	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
118	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
119	Alffenaar JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR "Omeprazole significantly reduces posaconazole serum trough level." Clin Infect Dis 48 (2009): 839. [PMID: 19220151]
120	Canadian Pharmacists Association.
121	Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ "Multicenter study of posaconazole therapeutic drug monitoring: exposure-response and factors affecting concentration." Antimicrob Agents Chemother 56 (2012): 5503-10. [PMID: 22890761]
122	Krishna G, Abutarif M, Xuan F, Martinho M, Angulo D, Cornely OA "Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome." Pharmacotherapy 28 (2008): 1223-32. [PMID: 18823218]
123	Krishna G, Moton A, Ma L, Medlock MM, McLeod J "The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers." Antimicrob Agents Chemother 53 (2009): 958-66. [PMID: 19075045]
124	Neubauer WC, Engelhardt M, Konig A, et al. "Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method." Antimicrob Agents Chemother 54 (2010): 4029-32. [PMID: 20547790]
125	Product Information. Noxafil (posaconazole). Schering-Plough Corporation, Kenilworth, NJ.
126	Shields RK, Clancy CJ, Vadnerkar A, et al "Posaconzaole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy." Antimicrob Agents Chemother 55 (2011): 1308-11. [PMID: 21189337]
127	Vaes M, Hites M, Cotton F, et al. "Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplasic syndrome." Antimicrob Agents Chemother 56 (2012): 6298-303. [PMID: 23027198]
128	Walravens J, Brouwers J, Spriet I, Tack J, Annaert P, Augustijns P "Effect of pH and Comedication on Gastrointestinal Absorption of Posaconazole: Monitoring of Intraluminal and Plasma Drug Concentrations." Clin Pharmacokinet 50 (2011): 725-34. [PMID: 21973269]
129	Krishna G, Moton A, Ma L, Malavade D, Medlock M, McLeod J "Effect of gastric pH, dosing regimen and prandial state, food and meal timing relative to dose, and gastro-intestinal motility on absorption and pharmacokinetics of the antifungal posaconazole." 18th European Congress of Clinical Microbiology and Infectious Diseases April (2008): 20.
130	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
131	Product Information. Epclusa (sofosbuvir-velpatasvir). Gilead Sciences, Foster City, CA.
132	Bradford GS, Taylor CT "Omeprazole and vitamin B-12 deficiency." Ann Pharmacother 33 (1999): 641-3. [PMID: 10369631]
133	Dutta SK "Vitamin b-12 malabsorption and omeprazole therapy." J Am Coll Nutr 13 (1994): 544-5. [PMID: 7706583]
134	Lavy NW "Omeprazole and vitamin B12." Ann Intern Med 121 (1994): 74. [PMID: 8198354]
135	Marcuard SP, Albernaz L, Khazanie PG "Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin-b12)." Ann Intern Med 120 (1994): 211-5. [PMID: 8273984]
136	Salom IL, Silvis SE, Doscherholmen A "Effect of cimetidine on the absorption of vitamin B12." Scand J Gastroenterol 17 (1982): 129-31. [PMID: 7134827]
137	Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
138	Lebsack ME, Nix D, Ryerson B, et al "Effect of gastric acidity on enoxacin absorption." Clin Pharmacol Ther 52 (1992): 252-6. [PMID: 1526081]
139	Misiak PM, Eldon MA, Toothaker RD, Sedman AJ "Effects of oral cimetidine or ranitidine on the pharmacokinetics of intravenous enoxacin." J Clin Pharmacol 33 (1993): 53-6. [PMID: 8429114]
140	Albin H, Vincon G, Begaud B, Bistue C, Perez P "Effect of aluminum phosphate on the bioavailability of ranitidine." Eur J Clin Pharmacol 32 (1987): 97-9. [PMID: 3582475]
141	Albin H, Vincon G, Demotes-Mainard F, et al "Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone." Eur J Clin Pharmacol 26 (1984): 271-3. [PMID: 6723769]
142	Barzaghi N, Gatti G, Crema F, Perucca E "Impaired bioavailability of famotidine given concurrently with a potent antacid." J Clin Pharmacol 29 (1989): 670-2. [PMID: 2569486]
143	Bodemar G, Norlander B, Walan A "Diminished absorption of cimetidine caused by antacids." Lancet 02/24/79 (1979): 444-5. [PMID: 84296]
144	Covington TR, Lawson LC, Young LL, eds. "Handbook of Nonprescription Drugs. 10th ed." Washington, DC: American Pharmaceutical Association (1993):.
145	Donn KH, Eshelman FN, Plachetka JR, et al "The effects of antacid and propantheline on the absorption of oral ranitidine." Pharmacotherapy 4 (1984): 89-92. [PMID: 6326064]
146	Lin JH, Chremos AN, Kanovsky SM, Schwartz S, Yeh KC, Kann J "Effects of antacids and food on absorption of famotidine." Br J Clin Pharmacol 24 (1987): 551-3. [PMID: 2891370]
147	Mihaly GW, Marino AT, Webster LK, Jones DB, Louis WJ, Smallwood RA "High dose of antacid (Mylanta II) reduces bioavailability of ranitidine." Br Med J 285 (1982): 998-9. [PMID: 6289961]
148	Russell WL, Lopez LM, Normann SA, et al "Effect of antacids on predicted steady-state cimetidine concentrations." Dig Dis Sci 29 (1984): 385-9. [PMID: 6714054]
149	Shelly DW, Doering PL, Russell WL, Guild RT, Lopez LM, Perrin J "Effect of concomitant antacid administration on plasma cimetidine concentrations during repetitive dosing." Drug Intell Clin Pharm 20 (1986): 792-5. [PMID: 3769772]
150	Steinberg WM, Lewis JH, Katz DM "Antacids inhibit absorption of cimetidine." N Engl J Med 307 (1982): 400-4. [PMID: 7088113]
151	Product Information. Inlyta (axitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
152	Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
153	Product Information. Effient (prasugrel). Lilly, Eli and Company, Indianapolis, IN.
154	Small DS, Farid NA, Payne CD, et al. "Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel." J Clin Pharmacol 48 (2008): 475-84. [PMID: 18303127]
155	Product Information. Isentress (raltegravir). Merck & Company Inc, West Point, PA.
156	Product Information. Erivedge (vismodegib). Genentech, South San Francisco, CA.

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence